Olesia Buiakova

Olesia Buiakova has a long and impressive career in the field of pre-clinical contract research. Olesia began their career in 1992 as a Postdoctoral Fellow at F. Hoffmann La Roche. Olesia then moved to Columbia Genome Center (Columbia University) as a Postdoctoral Researcher in 1995. In 1999, they became a Senior Scientist II at DNX Transgenic Sciences. In 2001, they moved to Xenogen Bioscience as a Senior Scientist III/ Project Manager, where they built and managed a multidisciplinary team of Ph.D. and M.Sc. scientists. Olesia was then promoted to Director and Associate Director at Xenogen Bioscience in 2003. In 2007, they became a Director at Caliper Life Sciences. In 2009, they were appointed Director at Taconic, where they managed a multidisciplinary team of scientists performing phenotypic characterization of GEMMs and led efforts for developing and expanding a contract research portfolio of state-of-the-art in vivo mouse models for evaluating therapeutic approaches in the areas of oncology, CNS, immunology and metabolic disease. In 2013, they joined Invivotek LLC, a Genesis Biotechnology Group Company, as Chief Scientific Officer and Vice President Biology, where they headed a multidisciplinary pre-clinical contract research team of Ph.D. and M.Sc. scientists. In 2019, they were appointed Senior Director In Vivo Pharmacology at Skyhawk Therapeutics.

Olesia Buiakova completed their M.D. in Clinical Biochemistry from The Russian State Medical University between 1981 and 1987.